SecurityAUPH / Aurinia Pharmaceuticals Inc (05156V102)
Institutional Owners68
Institutional Shares16,733,039
Institutional Value$ 96,213,000 USD

Institutional Stock Ownership and Shareholders

AUPH / Aurinia Pharmaceuticals Inc Institutional Ownership

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) has 68 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 16,733,039 shares. Largest shareholders include NEA Management Company, LLC, Polar Capital LLP, Goldman Sachs Group Inc, Franklin Resources Inc, Vivo Capital, LLC, BlackRock Inc., Abingworth LLP, Ameriprise Financial Inc, Susquehanna International Group, Llp, and Hudson Bay Capital Management LP.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR ROYAL BANK OF CANADA 16,168 16,954 4.86 84 95 13.10
2018-08-14 13F-HR Patriot Financial Group Insurance Agency, LLC 12,200 12,200 0.00 62 69 11.29
2018-08-14 13F-HR FIFTH THIRD BANCORP 2,000 2,000 0.00 10 11 10.00
2018-08-14 13F-HR DEUTSCHE BANK AG\ 23,155 13,987 -39.59 119 78 -34.45
2017-05-15 13F-HR R&F Capital Advisors LP 42,576 313
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 50,922 0 -100.00 264 0 -100.00
2018-08-14 13F-HR Man Group plc 32,800 58,500 78.35 170 329 93.53
2018-08-13 13F-HR Bayesian Capital Management, LP 16,300 0 -100.00 85 0 -100.00
2018-08-14 13F-HR AMERIPRISE FINANCIAL INC 259,854 299,992 15.45 1,349 1,689 25.20
2018-08-14 13F-HR FRANKLIN RESOURCES INC 1,664,400 1,733,200 4.13 8,638 9,758 12.97
2018-08-09 13F-HR Swiss National Bank 92,400 92,400 0.00 486 530 9.05
2018-07-20 13F-HR Creative Planning 158,200 171,200 8.22 821 964 17.42
2018-07-30 13F-HR Daiwa Securities Group Inc. 464 464 0.00 2 3 50.00
2018-08-14 13F-HR BROWN BROTHERS HARRIMAN & CO 6,500 6,500 0.00 34 37 8.82
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 1,208 2,182 80.63 6 12 100.00
2018-08-10 13F-HR Cutler Group LP Put 0 5,000 0 2
2018-08-14 13F-HR Abingworth LLP 252,129 400,434 58.82 1,309 2,250 71.89
2018-07-19 13F-HR BENJAMIN F. EDWARDS & COMPANY, INC. 2,000 11
2018-08-14 13F-HR Tower Research Capital LLC (TRC) 3,273 0 -100.00 18 0 -100.00
2018-05-11 13F-HR CITIGROUP INC 4,835 3,366 -30.38 23 18 -21.74
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 41,500 44,800 7.95 215 252 17.21
2018-07-20 13F-HR Steward Partners Investment Advisory, Llc 500 500 0.00 2 3 50.00
2018-07-30 13F-HR Trustcore Financial Services, Llc 4,590 26
2018-08-09 13F-HR NEA Management Company, LLC 4,808,483 4,808,483 0.00 24,956 27,072 8.48
2018-08-13 13F-HR GROUP ONE TRADING, L.P. Call 43,700 101,900 133.18 227 574 152.86
2018-08-06 13F-HR TORONTO DOMINION BANK 0 5,730 0 33
2018-08-14 13F-HR Alyeska Investment Group, L.P. 576,324 188,709 -67.26 2,991 1,062 -64.49
2018-07-13 13F-HR Minichmacgregor Wealth Management, Llc 360 0 -100.00 1 0 -100.00
2018-07-20 13F-HR Cornerstone Wealth Management, LLC 11,100 2,000
2018-08-14 13F-HR STIFEL FINANCIAL CORP 21,718 41,818 92.55 113 236 108.85
2018-08-13 13F-HR ProShare Advisors LLC 38,861 35,384 -8.95 202 199 -1.49
2018-08-10 13F-HR Vivo Capital, LLC 1,213,290 1,213,290 0.00 6,297 6,831 8.48
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 1,241,995 1,834,325 47.69 6,446 10,327 60.21
2018-08-14 13F-HR/A CITADEL ADVISORS LLC Call 26,600 25,700 -3.38 138 145 5.07
2018-08-13 13F-HR Hudson Bay Capital Management LP 300,000 230,000 -23.33 1,557 1,295 -16.83
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 131,030 100,930 -22.97 680 568 -16.47
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 24,217 19,260 -20.47 126 108 -14.29
2018-08-14 13F-HR/A CITADEL ADVISORS LLC Put 44,000 39,600 -10.00 228 223 -2.19
2018-08-14 13F-HR BARCLAYS PLC 1,020 30 -97.06 5 0 -100.00
2018-07-30 13F-HR Parallel Advisors, LLC 2,000 500 -75.00 10 2 -80.00
2018-08-14 13F-HR DRW Securities, LLC 31,300 31,300 0.00 162 176 8.64
2018-07-30 13F-HR Raymond James Financial Services Advisors, Inc. Put 19,000 18,500 -2.63 97 85 -12.37
2018-08-13 13F-HR GROUP ONE TRADING, L.P. 146,851 79,790 -45.67 762 449 -41.08
2018-08-08 13F-HR STATE TREASURER STATE OF MICHIGAN 22,500 0 -100.00 117 0 -100.00
2018-08-03 13F-HR Financial Architects, Inc 2,000 2,000 0.00 10 11 10.00
2018-08-10 13F-HR Legal & General Group Plc 2,329 2,329 0.00 12 13 8.33
2018-08-10 13F-HR Krasney Financial LLC 750 4
2018-08-09 13F-HR Stanley-Laman Group, Ltd. 48,994 276
2018-08-06 13F-HR Zurcher Kantonalbank (Zurich Cantonalbank) 698 4
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 95,028 210,521 121.54 493 1,185 140.37
2018-08-14 13F-HR D. E. Shaw & Co., Inc. 232,633 115,472 -50.36 1,207 650 -46.15
2018-08-10 13F-HR Shell Asset Management Co 5,200 5,200 0.00 27 30 11.11
2018-04-18 13F-HR Integral Derivatives, LLC Call 10,000 0 -100.00 45 0 -100.00
2018-08-10 13F-HR Cutler Group LP Call 4,800 5,500 14.58 0 5
2018-08-13 13F-HR GROUP ONE TRADING, L.P. Put 215,600 125,500 -41.79 1,119 707 -36.82
2018-08-10 13F-HR CITIGROUP INC 3,366 3,000 -10.87 18 17 -5.56
2018-08-10 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 3,000 3,000 0.00 16 16 0.00
2018-08-14 13F-HR INFRASTRUCTURE CAPITAL ADVISORS, LLC 22,003 0 -100.00 114 0 -100.00
2018-07-30 13F-HR/A Virtu Financial LLC 0 17,511 0 99
2018-07-30 13F-HR Raymond James Financial Services Advisors, Inc. Call 0 18,600 0 7
2018-08-08 13F-HR IRONWOOD INVESTMENT MANAGEMENT LLC 185,289 218,568 17.96 962 1,231 27.96
2018-08-14 13F-HR UBS Group AG 115,435 120,435 4.33 599 678 13.19
2018-08-07 13F-HR LEVIN CAPITAL STRATEGIES, L.P. 10,000 10,000 0.00 52 56 7.69
2018-08-14 13F-HR Kazazian Asset Management, LLC 156,126 170,356 9.11 810 959 18.40
2018-05-15 13F-HR We Are One Seven, Llc 11,000 11,000 0.00 50 57 14.00
2018-08-10 13F-HR Cutler Group LP 600 0 -100.00 3 0 -100.00
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ Put 10,300 10,300 0.00 53 58 9.43
2018-08-09 13F-HR BlackRock Inc. 1,045,121 980,339 -6.20 5,424 5,520 1.77
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 700 700 0.00 4 4 0.00
2018-07-30 13F-HR SIMPLEX TRADING, LLC 16,606 36,768 121.41 86 207 140.70
2018-07-11 13F-HR TRUST CO OF VERMONT 1,000 1,000 0.00 5 6 20.00
2018-08-14 13F-HR BOOTHBAY FUND MANAGEMENT, LLC 0 36,000 0 203
2018-08-14 13F-HR TWO SIGMA ADVISERS, LP 37,900 25,900 -31.66 197 146 -25.89
2018-07-31 13F-HR HOWE & RUSLING INC 387 387 0.00 2 2 0.00
2018-08-14 13F-HR A.R.T. Advisors, LLC 0 55,595 0 312
2018-08-14 13F-HR MORGAN STANLEY 607,361 76,139 -87.46 3,151 429 -86.39
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 245,800 230,900 -6.06 1,276 1,300 1.88
2018-08-14 13F-HR CREDIT SUISSE AG/ 28,300 22,878 -19.16 147 128 -12.93
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 24,941 64,985 160.55 129 365 182.95
2018-08-14 13F-HR Candriam Luxembourg S.C.A. 118,000 157,500 33.47 612 887 44.93
2018-08-14 13F-HR VANGUARD GROUP INC 14,771 14,771 0.00 77 83 7.79
2018-08-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 6,730 6,730 0.00 35 36 2.86
2018-08-14 13F-HR Polar Capital LLP 2,500,000 2,600,200 4.01 12,975 14,639 12.82
2018-08-03 13F-HR Cutler Capital Management, LLC 55,000 55,000 0.00 285 310 8.77
2017-07-13 13F-HR Princeton Alpha Management LP 12,900 0 -100.00 95 0 -100.00
2018-08-14 13F-HR ORBIMED ADVISORS LLC 626,275 167,419 -73.27 3,250 943 -70.98
2018-07-30 13F-HR Raymond James Financial Services Advisors, Inc. 28,750 27,200 -5.39 149 153 2.68
AUPH: Aurinia Pharmaceuticals Stock Analysis and Research Report

2017-09-28 - Asif

Aurinia is a clinical stage biopharmaceutical company with its head office located at #1203-4464 Markham Street, Victoria, British Columbia V8Z 7X8 where clinical, regulatory and business development functions of the Company are conducted. Aurinia has its registered office located at #201, 17904-105 Avenue, Edmonton, Alberta T5S 2H5 where the finance function is performed. The office of the CEO is located in Bellevue, Washington. Aurinia is organized under the Business Corporations Act (Alberta). Aurinia’s By-Law No. 2 was amended at a shareholder’s meeting held on August 15, 2013 to include provisions requiring advance notice for any nominations of directors by shareholders. Aurinia’s Common Shares are currently listed and traded on the NASDAQ under the symbol “AUPH” and on the TSX under the symbol “AUP”. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular LN. Aurinia has the following wholly-owned subsidiaries: ...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Aurinia And Voclosporin: Making A Difference In Focal Segmental Glomerulosclerosis

7h seekingalpha
Voclosporin is an immunosuppressive/anti-inflammatory investigative drug candidate in clinical trials for lupus nephritis, dry eye syndrome as well as focal segmental glomerulosclerosis, the focus of this article. (2-0)

2018 Is An Ideal Entry Point For Aurinia Pharmaceuticals

2018-09-10 seekingalpha
Voclosporin is in Phase III trials for treatment of lupus nephritis (LN) and has a high probability of FDA approval based on Phase IIb data. (17-4)

Your Daily Scoop: Anifrolumab Flunks, Aquestive Approved, Vertex's CRISPR Trial In Germany

2018-09-03 seekingalpha
Discussion: AstraZeneca (AZN) announced failure of a Phase 3 trial of its anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (‘SLE). The drug failed to achieve a statistically valid reduction in disease activity at month 12 as measured by a scale called SRI4. Reduction in SRI4 value was the primary endpoint of the trial. Shares slipped marginally by 1% in the negative news. (28-0)

Aurinia Pharmaceuticals' (AUPH) CEO Richard Glickman on Q2 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Greetings. Welcome to Aurinia Pharmaceuticals Incorporated Q2 2018 Financial Results. At this time, all participants are in a listen only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (1-2)

Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

2018-08-09 zacks
Aurinia Pharmaceuticals (AUPH - Free Report) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items. (1-2)

Take Advantage Of Poor Market Sentiment And Buy Esperion Therapeutics

2018-07-17 seekingalpha
Bempedoic Acid will be a winner in the LDL-C reduction and cardiovascular disease prevention markets, as both a monotherapy and add-on to existing treatments. (2-5)

Aurinia Pharmaceuticals Has Lots of Upside Potential

2018-07-13 investorplace
Since last year, Aurinia Pharmaceuticals (NASDAQ:AUPH) has moved very little on the stock market. It is now in a holding pattern, in the range of $4.50 to $6. News of the launch of a mid-stage study, along with a quarterly earnings report before that, failed to ignite or hurt AUPH stock by much. Yet both events suggest that the company is on the right path. (1-6)

Your Daily Pharma Scoop: ResTORbio Progresses, Roche Closer To Review, AbbVie Falters

2018-07-13 seekingalpha
Discussion: ResTORbio (TORC) announced positive results from a Phase 2a clinical trial of its lead drug RTB101 in elderly patients. The candidate was on trial testing its infection-lowering ability. The datasets were published in Science Translational Medicine. The study showed that RTB101 both as monotherapy as well as in combination with Novartis’s Afinitor (everolimus), showed statistically significant reduced rate of respiratory tract infections. (33-0)

Your Daily Pharma Scoop: IPO Review - Aptinyx Surges, Kezar Progresses, Neon Slumps

2018-07-11 seekingalpha
Aptinyx (APTX) priced its IPO at $16.00. 6.4M common stock shares were offered. Additional 959,999 shares were on underwriters over-allotment. Gross proceeds initially expected was ~102.4M, but reached $117.8M by the time of closing. The shares opened at $17.40 on June 21. The IPO closed on June 25. (28-2)

BioSpace Movers and Shakers for Week of June 4th

2018-06-12 biospace
Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors. The companies filled the roles with the talent they believe will drive the next stage of growth. (286-4)

CUSIP: 05156V102